Article Information
History
- February 5, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Charles W. Bishopa,
- Akhtar Ashfaqa,
- Joel Z. Melnickb,
- Enrique Vazquez-Escarpanterc,
- Jonathan A. Fialkowd,
- Stephen A. Strugnella,*,
- John Choea,
- Kamyar Kalantar-Zadehe,
- Noah C. Federmanf,
- David Ngg and
- John S. Adamsg
- aRenal Division, OPKO Health, Miami, FL, USA
- bSCDadvisor, Evanston, IL, USA
- cKendall South Medical Center, Miami, FL, USA
- dCardiovascular Research Center of South Florida, Miami, FL, USA
- eDivision of Nephrology, Hypertension and Kidney Transplantation, University of California Irvine, Orange, CA, USA
- fDepartment of Pediatrics, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
- gWuXi Clinical Development, Austin, TX, USA
- hDepartment of Orthopaedic Surgery and Molecular, Cell and Developmental Biology, UCLA, Los Angeles, CA, USA
- ↵*Corresponding Author:
Stephen A. Strugnell, PhD, Senior Director, Scientific Affairs Renal Division, OPKO Health, Inc. 4400 Biscayne Blvd. Miami, FL 33137 (USA), sstrugnell{at}opko.com
Posted February 05, 2022.
Results From the REsCue Trial: A Randomized Controlled Trial with Extended-Release Calcifediol in Symptomatic Outpatients with COVID-19
